BioLineRx (BLRX) Total Liabilities (2010 - 2025)

BioLineRx's Total Liabilities history runs 16 years deep, the most recent figure standing at $17.6 million for Q4 2025.

• On a quarterly basis, Total Liabilities fell 30.99% year-over-year to $17.6 million in Q4 2025; TTM through Dec 2025 was $17.6 million, a 30.99% decrease from a year earlier, with the FY2025 full-year figure at $17.6 million, down 30.99% from the prior year.
• Total Liabilities declined to $17.6 million in Q4 2025 per BLRX's latest filing, from $20.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $50.7 million in Q4 2023 and bottomed at $11.3 million in Q2 2022.
• The 5-year median for Total Liabilities is $24.3 million (2024), against an average of $27.0 million.
• Across the five-year window, Total Liabilities soared 236.13% in 2023 and slumped 54.18% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $13.3 million in 2021, then soared by 91.99% to $25.5 million in 2022, then soared by 98.5% to $50.7 million in 2023, then plunged by 49.81% to $25.4 million in 2024, then sank by 30.99% to $17.6 million in 2025.
• Per Business Quant, the three latest BLRX Total Liabilities figures stand at $17.6 million (Q4 2025), $20.3 million (Q3 2025), and $23.2 million (Q2 2025).